Rett syndrome (RTT) is an X-linked neurodevelopmental disorder in which the MECP2 (methyl CpG-binding protein 2) gene is mutated. Recent studies showed that RTT-derived neurons have many cellular deficits when compared to control, such as: less synapses, lower dendritic arborization and reduced spine density. Interestingly, treatment of RTT-derived neurons with Insulin-like Growth Factor 1 (IGF1) could rescue some of these cellular phenotypes. Given the critical role of IGF1 during neurodevelopment, the present study used human induced pluripotent stem cells (iPSCs) from RTT and control individuals to investigate the gene expression profile of IGF1 and IGF1R on different developmental stages of differentiation. We found that the thyroid hormone receptor (TRalpha 3) has a differential expression profile. Thyroid hormone is critical for normal brain development. Our results showed that there is a possible link between IGF1/IGF1R and the TRalpha 3 and that over expression of IGF1R in RTT cells may be the cause of neurites improvement in neural RTT-derived neurons.
Introduction
Rett syndrome (RTT; OMIM 312750) is an X-linked neurodevelopmental disease that affects mainly girls (1) (2) (3) . Boys with the disease are severely affected and, in most cases, die early in the development (3) . Mutations on the methyl-CpG binding protein 2 (MECP2) gene are found in nearly all the cases of RTT. MECP2 expression occurs in all tissues, however its major complication affects the central nervous system (4) . The MeCP2 protein works by binding into the genome and controlling the expression of several genes, such as Insulin-like Growth Factor 1 (IGF1), brain-derived neurotrophic factor (BDNF) and N-methyl-D-aspartate (NMDA) (5) . Moreover, MECP2 gene duplication also yields to a severe neurodevelopmental disorder (MECP2 Duplication Syndrome), suggesting that its expression should be tightly controlled to a normal development of the nervous system (6, 7) .
IGF1 deficiency in mice causes reduced postnatal brain growth. The brain growth arrest is likely a result of reduced neuronal size, since the number of cells is similar to control animals (8, 9) . It was already shown (10) that IGF1 treatment could significantly increase dendritic growth of cortical slices. Glutamatergic neurons, derived from RTT patient iPSCs, have decreased synapses, reduced dendritic spines, and an imbalance in the neural network (11) . Interestingly, IGF1 treatment was able to increase the number of synapses on those neurons. Furthermore, studies also revealed an improvement in cognition and interactions with the surrounding environment in RTT patients treated with IGF1 (2, 12) .
The action of IGF1 is through IGF1 receptor (IGF1R), but could also interact with the insulin receptor. IGF1R is found in all tissues. The interaction between IGF1 and IGF1R is modulated by IGF binding proteins (IGFBPs) (13) (14) (15) . IGF1R is widely expressed in the brain and can co-localize, in many regions, with the insulin receptor (8, 16) . IGF1 is an endocrine hormone mainly produced by the liver (8, 17, 18) . This hormone mRNA is abundant in the brain, with a higher expression during postnatal development (19) . IGF1 is found mainly in growing projection neurons in sensory and the cerebellar relay system, where IGF1R is also highly expressed, suggesting an autocrine or paracrine mode of action (8) . IGF1 protects neurons, reducing neurodegeneration and prolonging life span of cells (20, 21) . It is also important to neurodevelopment modulation, being fundamental to proliferation and neural maturation (16) .
Production of IGF1 is stimulated by growth hormone (GH) produced by pituitary (8, 17, 18, 20, 22) . Oestrogen is another hormone that mediates regulation of IGF1 (23) . Thyroid hormone also affects IGF1 concentration in plasma (24) , since this hormone influences GH/IGF1 axis (25) . In an elegant study (26) it was shown that TH controls IGF1 action throughout an integrin amb3. In Muscle cells, IGF1 binds to its receptors and stimulate tyrosine kinase and PI3K activities. Interestingly, T4 may inhibit the action of IGF1 in glucose homeostasis, impairing cell proliferation, signalling and growth.
IGF1 is an important hormone to insulin homeostasis and is sensitive to minor alterations, such as bisphenol A and dexamethasone exposure during rats' pregnancy resulted in offspring with TH, GH and IGF1 serum concentration altered, which may lead to a delay in the neurodevelopment (27, 28) .
Brain is an important target of thyroid hormones (THs) (pro hormone tiroxine, T4 and the active form 3,5,3'-triiodotironine, T3). During brain maturation THs influence the development process, differentiation, myelination, neural and glial signalling (29) (30) (31) . Deficiency on TH function may impair neural differentiation, survive and neurogenesis and its replacement restore cognition and all defects caused by TH deficit (32, 33) . TH actions are mediated by nuclear receptors located in specific regions of DNA, when THs are bonded to their receptors there is transcriptional activation or inhibition of target genes and proteins that they encode (34, 35) .
Two genes, THRalpha and THRbeta, originated by alternative splicing, encode different forms of TH receptors: TRalpha 1, TRalpha 2, TRbeta 1, TRbeta 2. These isoforms are expressed in different tissues (36, 37) . TRalpha 3 is encoded by transcript variant 3. Studies using knockout mice of different TH receptors showed that, besides the similarity of these receptors, they have different functions in TH signalling. The variant 3 resembles to variant 2 (NM_001190918.1), however TRalpha 2 is an isoform that is not responsive to TH, it does not bind to T3, since it lacks functional ligand-binding domain (38, 39) .
The aim of this study was to investigate the gene expression profile of IGF1 and its receptor from the stage of iPSC until neural cells from a derived line cell from a male RTT patient carrying a stop codon mutation with no protein synthesis. Furthermore, it was exhibited in the rescue of the neurites length in RTT neurons after treatment with IGF1, and this result is possible since RTT neurons have an increased expression of IGF1R. Finally, our data revealed a possible correlation between the expression levels of TRalpha 3 and IGF1, revealing a likely mechanism of IGF1/IGF1R regulation.
Since there are an overlap of RTT features and other diseases and/or neurodevelopmental syndromes in which intellectual impairment, such as the autism spectrum disorder (ASD) is included (40) , it is important to understand RTT and find a therapeutic exit to this syndrome that may contribute to the treatment of a variety of neurodevelopmental disease.
Results

Cells characterization
The canonical markers of pluripotent state Oct4, Tra 1-81 and Lin28 were used to characterize RTT and control iPSCs (Fig. 1A) . NPCs were stained with antibodies targeting Sox2 and Nestin, two markers of neural precursors (Fig. 1B) . Finally, 6 weeks old neural culture cells were stained with Map2 and Synapsin 1 antibodies, targeting two classical markers of neurons (Fig. 1C) .
Maintenance of iPSCs and NPCs in culture requires several cell passages, a procedure that can lead to chromosomal abnormalities. To verify any chromosomal aberrancy acquired during the process of maintenance of the cells, karyotyping was performed at the NPC stage, before the cells were differentiated in neurons. The results show a normal karyotype for all cells used on this study (Fig. 1D) .
As part of cell characterization it was also performed a qRT-PCR at the stages of iPSC, NPC and Neural cells to show specific gene expression at each stage. The gene expression profiles of the three cellular stages were compared to each other. Supplementary Material, Fig. S1A An open question in the field is if IGF1 expression is altered during the development of the nervous system. Interestingly, we did not detect any difference between RTT and control neurons ( Fig. 2A) . We also checked the expression of thyroid hormone receptor alpha 3 (TRalpha 3). Similarly to IGF1, this gene did not present a significant difference between RTT and control neurons (Fig. 2B) . compared to the other developmental stages. In RTT the increasing was approximately 35000 times compared to the other stages. Meanwhile, IGF1R expression was present in all stages in both control and RTT, as shown in Fig. 4B . Interestingly, at the EB stage (cell stage 2), both control and RTT had an increase of approximately 3 times the expression found on iPSC stage. However, only RTT displays an increase in the neural stage when compared to iPSC.
We also studied the expression of TRalpha 3, a thyroid hormone receptor. In our results it was shown that this gene expression is similar to the IGF1 expression. TRalpha 3 gene expression was only detected in neural stage in both control and RTT cells ( To test the concentration of IGF1 during the neural differentiation, we performed ELISA analysis at 3 weeks of differentiation. The levels of this hormone in the media did not change when compared to control media (media without cells; Table 1 ). On the other hand, the concentration of IGF1 from medium of 6 week-mature neurons decreases significantly compared to control media and to 3 week-differentiated cells. Comparing the concentration of IGF1 from the medium of 3 week-old cells with 6 week-old cells, in both (control and RTT) is possible to observe that at six weeks of differentiation concentration decreases 2.6 times compared to 3 week-differentiated neural cell medium.
When these cells were treated with thyroid hormone at 3 weeks of differentiation the concentration of IGF1 did not change after two days of treatment. However, at 6 weeks of differentiation, when these cells were treated with thyroid hormone, the consumption of IGF1 was higher in RTT T3 10 À6 M (0.07072 64.7330 ). It is important to notice that there is no significant difference between these controls in IGF1 consumption. Q83X T3 10 
Treatment of neural cells with IGF1 increases neurite length of Rett syndrome neurons
In Rett syndrome one of the characteristics of the subject is the abnormal neurodevelopment. Several studies had shown that IGF1 could improve neural morphology and function. Here we took maturate neural cells, and treated them with this hormone Fig. 5A . These cells were treated with IGF1 for 14 days at a concentration of 10 lM. Control neurons that were treated with IGF1 did not present any significant difference (data not shown) compared to untreated control. The length of neurites (Fig. 5B ) from control was 380 lm, and the length from RTT was 250 lm, these results showed that the RTT neurites length is approximately 35% shorter than those from control. On the other hand, when RTT cells were treated with IGF1 the length of neurites increased in treated cells compared to untreated RTT neurons, practically rescuing the total neurite length to control levels.
The absence of MECP2 function alters the expression of thyroid hormone receptors Thyroid hormone receptors are important to cell genomic response to the hormone and its biological action (41) . In Rett syndrome, it was shown that the cause of the syndrome is the absence of MECP2 function (11) and in our study we demonstrated significant alteration in expression of TH receptors. At the iPSC stage (Fig. 6A) The gene expression of THRB1 in control cells (Fig. 7B ) during cell differentiation increased 33.6-fold and 19.1-fold, respectively, in neural cells (5.7210 62.3890) compared to NPC (0.1746 60.0158) and EB (0.2952 60.0849), and decreased 6.9-fold in NPC compared to iPSC (1.1770 60.2823). In RTT cells (Fig. 7B) , the expression of THRB1 significantly increased in neural cells (11.0200 64.2610), 24-fold compared to NPC (0.4582 60.1707) and 10.4-fold compared to EB (0.6519 60.2192).
THRB2 gene expression was also analysed and in control cells (Fig. 7C) , at the neural cell stage (3.5200 61.4270), the expression increased 32-fold compared to NPC (0.1133 60.0135) and 22-fold compared to EB (0.1569 60.0617). NPC gene expression decreased 11.2-fold compared to iPSC expression (1.2310 60.3381). In RTT cells (Fig. 7C) Thyroid hormone receptors may form dimers with other nuclear receptors, such as RXR family receptors (Retinoid X Receptor). The expression of RXRG in control cells (Fig. 7D) increased at the EB stage (28.8500 69.3730) 20.56-fold compared to iPSC (1.4130 60.4357), and also increased at the neural cell stage (91.9100 642.4400) 65.2-fold compared to iPSC. In RTT (Fig.  7D ) the expression at the neural cell stage (363.4000 6121.7000) increased 300.3-fold compared to iPSC (1.2070 60.2678) and 34.6-fold compared to NPC (10.5000 63.3040).
Correlation analysis of investigated genes
In addition to the presented results, the correlation of the expression of studied genes at neural cell stage was also evaluated. Pearson correlation analysis showed a highly significant association between IGF1 Receptor gene expression and S.E.M.
TRalpha 3 gene expression (r ¼ 0.644) ( Table 2 ). The expression of IGF1 has a significant positive correlation with THRB1 (r ¼ 0.725) and THRB2 (r ¼ 0.638). THRA1 has a significant positive correlation with IGF1R (r ¼ 0.833) and THRA3 (r ¼ 0.699). THRB1 has a strong correlation with THRB2 (r ¼ 0.976). RXRG has a negative correlation with THRB2 (r¼À0.583) and THRB1 (r¼À0.535), which means that the expression of these genes is inversely proportional.
Discussion
In this study, we use human iPSCs to investigate the expression profile of IGF1 during the development of the nervous system in RTT and control cells, given the recent findings that IGF1 could rescue some of the phenotypes in RTT neurons (2,11) and its importance in normal brain function (42) . MeCP2 regulates IGF1 and BDNF levels, and when this gene is mutated both proteins have their expression decreased (22) . In our study, we show that IGF1 gene expression was not different between control and RTT neurons. Interestingly, IGF1R has its gene expression increased in RTT neural cells compared to control.
Previous studies showed that IGF1 is expressed in the brain during the early stages of development. Our data revealed that the expression of IGF1 by the neural cells occurs at the final stages of differentiation of these cells, and there is no significant difference between IGF1 expression in control (WT83) and RTT (Q83X) neurons (8, 19) .
Several studies have already shown that IGF1 can recover neural function and morphology in Rett Syndrome after treatment (2, 11, 12, 22) . Additionally, IGF1R has been shown as having an important role in brain development. Mutations leading to loss-of-function of IGF1R may result in microcephaly, mental retardation and behavioural deficiency (20) .
Taking into account IGF1 role in RTT, in this study we showed gene expression of IGF1 and IGF1R from iPSC until neuronal cell stage in control and RTT. It was demonstrated that there is an IGF1 gene expression only during the neuronal cell stage, at 6 weeks of cell differentiation, which means that this expression occurs mainly at mature stage. From iPSC until NPC, there is very low IGF1 gene expression. With the presented results some conclusions can be inferred, such as that the presence of IGF1R since iPSC stage does not necessary means that this receptor is related individually to IGF1 signalling. It was shown (43) that extracellular vimentin interacts with an IGF1 receptor to promote axonal growth in cultured cortical neurons; therefore the expression of IGF1R, before the expression of an IGF1 by the neurons, can relate this protein to other functions. Likewise, the presence of IGF1R is necessary for axonal regeneration in the adult central nervous system (CNS), as well as for embryonic CNS axonal development (44) .
When the extracellular concentration of IGF1 was measured in the medium that neurons were cultured, no different changes in hormone concentration were detected at 3 weeks of differentiation. However, when we measured the IGF1 concentration on 6-weeks-old neural culture, the consumption of IGF1 increased considerably in both types of cells, control and RTT. Interestingly, when we examined the levels of IGF1R, we detected an increase of expression only in the RTT neurons. This increased expression of IGF1R may reflect the prompt response of these cells to treatment with IGF1, which is involved with the neuroprotective mechanisms after some neural damages (45) and is increased after injures in this fundamental tissue (46, 47) .
We hypothesized that TRalpha3, a subtype of thyroid hormone receptor, may be involved in regulating the expression of IGF1, since the expression of TRalpha3 occurs concomitantly with IGF1. Moreover, our work is the first to prove a strong correlation between IGF1R response to IGF1 and TRalpha3. It is noteworthy that there is a great possibility of the interaction among these genes. Unexpectedly, the treatment of neural cells with thyroid hormone at 3 and 6 weeks of differentiation seems to corroborate our hypothesis. The other subtypes of thyroid hormone receptors, such as TRalpha1, TRbeta1 and TRbeta2 are expressed in all studied stages of cell differentiation (iPSC, EB, NPC and neuronal cells - Fig. 7 ), after treatment of neuronal cells with TH only at Q83X 6-week-differentiated neural cells the consumption of IGF1 increased in both dosage of T3 treatments (10 -6 M and 10 -12 M). In order to assess whether the existing functional differences between THRA and THRB genes are derived from individual properties of each receptor, a study compared the responsive gene expression to T3 in two cell lines, one of which expresses the TRalpha1 and the other, the TRbeta1. This study showed that a considerable amount of target genes tested showed preference for one of the two receptors, indicating these receptors contribute unique characteristics and can determine its function, mainly during neurodevelopment (48) . To answer the new hypothesis, we will need more studies, but these present results give us a good hint that we are in the right direction to better understand the role of these studied genes.
This study has shown that the gene expression of TH receptors is affected in all cellular phases in RTT compared to the Control. They act differently in distinct stages of cell differentiation.
The effects of TH in the CNS are primarily mediated by TH receptors (TRs), members of the family of nuclear hormone receptors. The TRs bind to the regulatory regions of the DNA of target genes to activate or repress transcription through interactions with proteins known as co-regulators (49) .
The major isoforms of TRs are TRalpha1 and TRbeta1, both bind to TH and also have different biological functions (49) .
TRalpha1 corresponds to 70-80% of thyroid receptors in the brain, but there is still TRbeta1 and TRbeta2 expression (50) . TRbeta2 comprises 10% of receptors in various tissues, including the brain (51) . The expression of TRalpha1, which is important for CNS development, is higher in RTT compared with Control at the EB stage.
The lack of TRalpha1 in mice has a different result when compared to animals that have a mutation in this gene. The absence of TRalpha1 in the brain does not resemble hypothyroidism. In hypothyroidism, the receptor that is not bound to a hormone presents activity since the gene expression of some proteins that are negatively responsive to TH is induced. On the other hand, in the absence of the receptor, this activity is suppressed and hypothyroidism is not as damaging as in its presence (52) .
TRs can bind to DNA in its entirety as protein dimers, forming heterodimers with other members of the nuclear receptor family, such as the RXR (Retinoic X Receptor) or homodimers with themselves. TRs have bimodal regulation, typically connecting co-repressors to inactivate transcription of target genes, in the absence of TH. TH can also release co-repressors and recruit co-activators to activate transcription of target genes, which respond positively to the presence of this hormone (49) .
TRalpha1 is expressed early in embryonic development and then widespread in adults, while TRbeta1 is expressed late in embryonic development and displays a pattern of more restricted tissue expression in adults. TRalpha1 has a greater response to T4 than TRbeta1 (49) . The expression of the nuclear receptor RXRG, which forms dimers with TH receptors, significantly increased expression at the neural cell stage, showing its importance at this stage.
In humans, TH receptors are present around week 10 of embryonic development and gradually increase until week 18. It is in this period that the brain increases considerably in size (53) . This study found a pattern of increasing TH receptors during cell differentiation and the higher expression at the neural cell stage, corroborating with the literature.
Thyroid hormone has an important role in brain development and its function has rarely been studied in RTT, in which was shown to present prevalence of decreased concentration of serum free T4 (3). IGF1, a fundamental regeneration factor, was already shown as responsive to this hormone, such as other factors regulated by TH, Neuron Growth Factor (NGF) (54) (55) (56) (57) , Fibroblast Growth Factor (FGF), BDNF, Epidermal Growth factor (EGF), Vascular endothelial Growth factor (VEGF) (58) .
We conclude that increased IGF1R expression may be the key role for the improvement experienced by RTT-derived cells after treatment with IGF1 and that thyroid hormone receptor alpha 3 (TRalpha 3) may be involved with the responsiveness onset of the IGF1R to IGF1.
Materials and Methods
Ethics committee
This study was reviewed and approved by the UCSD Human Research Protections Program in accordance with the requirements of the Code of Federal Regulations on the Protection of Human Subjects and its reference number is 090801ZF. Recruited individuals were aware about study description, written informed consent was signed.
Cell culture
Induced pluripotent stem cells (iPSCs) IPSCs reprogrammed from skin fibroblasts were used in this study. Skin fibroblasts derived from male patient with Rett syndrome, with a nonsense mutation at position 83 of the protein (RTT), and a male control (WT83) were transduced with retroviral human vectors containing coding sequences of human 
Generation of embryoid bodies (EBs)
The iPSCs were treated for two days in N2 medium (DMEM/F-12 50/50, with L-glutamine and 15 mM HEPES; insulin; progesterone, sodium selenate, L-glutamine, HEPES, Apo-transferrin) with Dorsomorphin (DM) and SB431542 (Stemgent, Cambridge, MA, EUA). After these two days, the cells were resuspended and maintained in suspension for approximately 1 week with N2 medium (6).
Neural rosettes generation
After 5-7 days EBs were collected and gently resuspended and seeded in 6 cm coated matrigel plate, so rosettes formation would occur. For approximately 4 days rosettes were kept in NGF medium (DMEM/F-12 supplemented with 0.5X N2, 0.5X Gem21, 1X Penicillin/Streptomycin and 20ng/ml of bFGF) and then manually collected. After dissociation to single cells, the obtained Neural Progenitor Cells (NPCs) were plated on Polyornithine/Laminin plates and cultured with NGF medium (6).
NPCs expansion and neural differentiation
NPCs were propagated until the fifth passage in a density of 10 6 cells in Poly-ornithine/laminin plates using NGF medium. After this, they were seeded in six-well plates in a density of 7 x 10 5 cells per well. When these cells achieved 90% of confluence the differentiation was induced with NG medium (DMEM/F-12 supplemented with 0.5X N2, 0.5X Gem21 and 1X Penicillin/ Streptomycin) supplemented with Rock Inhibitor (Ri) for 48h, then the cells were kept in NG medium without Ri up to six weeks for neural maturation RNA extraction and qRT-PCR Total RNA was extracted using TRIzolV R Reagent (Life Technologies). cDNA was synthesized by taking 1 lg of total RNA and QuantiTec Reverse Transcription Kit (Qiagen) was used as the manufacturer's instruction. Quantitative reversetranscriptase PCR (qRT-PCR) was performed using gene-specific primers (Supplementary Material, Table S1 ) and QuantiTect SYBR Green PCR Kit (Qiagen). Quantification was made at ABI Prism 5700 detector (Applied Biosystems). The expression of target genes and the endogenous control were measured with technical duplicates in each qRT-PCR reaction. To obtain statistical significance, values from a minimum of three independent differentiation qRT-PCR runs were considered. GAPDH (Supplementary Material, Table S1 ) was used as the endogenous control. The cycle threshold number (Ct) was calculated by (Life Technologies, USA). The relative expressions of each target gene across differentiation days were normalized using 2 (ÀDDCt) method compared with control (60) .
Cell karyotyping
Cytogenetic analysis was performed in all clones to evaluate correct cell karyotype (Children's Hospital Los Angeles).
Immunocytochemistry
Cells grown on coverslips were fixed using 4% paraformaldehyde (PFA) for 20 min at room temperature (RT). Cells were permeabilized and blocked using a SuperBlock TM (Thermo Scientific) blocking buffer for 30 min at RT. Primary antibodies were diluted in antibody diluent (blocking buffer) and were incubated overnight at 4 C. Secondary antibodies were incubated for 1 h at RT. Cells were washed three times with phosphate-buffered saline (PBS) þ 0.1% Tween-20. DAPI (Dako) was used to visualize nuclei. Coverslips were mounted on slides using Prolong Gold mounting medium (Life Technologies). Images were acquired using confocal microscope Radiance 2100 (Zeiss, Oberkochen, Germany) equipped with an upright microscope (Eclipse E800; Nikon, Tokyo, Japan).
IGF1 hormonal dosage
After 48 h of cell treatment, the medium was collected in 1.5 ml vials and frozen until hormonal dosage. IGF1 concentration was determined by using an ELISA kit (Abnova, Taiwan) following the manufacturer's protocol.
Statistical analysis
The results were first submitted to the Kolmogorov-Smirnov normality test. The parameters were analysed by ANOVA one way when passed in normality test followed by Newman-Keuls Multiple Comparison Test, and KRUSKAL-WALLIS, followed by Dunn's multiple comparison test. Pearson correlation analysis was done to evaluate the relationship strength between variables obtained from the same sample. The r values range from þ1 toÀ1, where þ1 is an exact correlation and À1 is an exact inverse correlation. All analyses were performed with GraphPad Prism (La Jolla, California, USA). Statistical differences were considered significant when the value of P was lower than 0.05. The values were expressed as means and the standard error of the mean (6 SEM).
